Abbott AlphaTRAK, 95
acepromazine, 333
acromegaly
  in cat, 235. See also hypsomatotropism (HS), in cat
  in dog, 231. See also hypsomatotropism (HS), in dog
ACTH stimulation test, 166–167, 181
acyclovir, 447
Addison’s disease, 263. See also hypoadrenocorticism
ADH-responsive diabetes insipidus, see diabetes insipidus (DI)
ADH supplementation test, 75
adrenal tumor (AT), see canine hyperadrenocorticism (HAC)
agalactia, 325–336
  clinical features, 329
  definition, 325
  diagnostics, 331
  mammary gland ultrasound, 331–332
  pathological findings, 331
  differential diagnosis, 331
  etiology/pathophysiology, 325
  historic findings, 328
  risk factors, 327
  signalment/history, 326–327
  systems affected, 326
  therapeutics, 332–333
agalactorrhea, see agalactia
aglepristone, 341–342, 347, 348, 368, 371–373
alanine aminotransferase (ALT), 249
aldosterone, 477
aldosterone-to-renin ratio (ARR), 479
alfaprostol, 367, 372
allele, 147
amended insulin:glucose ratio (AIGR), 279
amine precursor uptake and decarboxylation (APUD) cells, 41
amoxicillin-clavulanic acid, 421
anesthesia and analgesia, cesarean section and, 47
anthelmentics, in pregnant and breeding dogs, 1–10. See also parasitic infection
antidiuretic hormone (ADH), and diabetes insipidus, 74
antimicrobial use
  bacteria and, 11
  clinical features, 12–13
  definition, 11
  diagnostics, 14
  indiscriminant use, 11
  in small animal reproduction, 11–14
  systems affected, 11
  therapeutics, 14
anti-Mullerian hormone (AMH), 63, 66, 400–401
antithyroid drugs, 255–257
APUDomas, 153, 409
arginine vasopressin (AVP), 517
aseptic mastitis, see galactostasis
autoimmune polyglandular syndromes (APSs), 17–21
  clinical features, 18–19
  complications, 20
  diagnostics, 19
  differential diagnosis, 19
  etiology/pathophysiology, 17–18
  signalment/history, 18
  therapeutics, 19–20
  type 1, 17
  type 2, 17
  type 3, 17
azithromycin, 443
bacteria-associated pregnancy loss, queen, 459–461
B-cell tumor, see insulinoma
benign adenomatous hyperplasia, 245. See also hyperthyroidism
benign prostatic hypertrophy (BPH), 483. See also canine prostate disease
bisphosphonates, 221
breeding management, of bitch, 23–31
  breeding plan, 25
  artificial insemination (AI), 25
  chilled-shipped semen, 25
  dual-sire breedings, 25
  fresh semen, 25
  frozen semen, 25
breeding management, of bitch (continued)
equipment, 23–24
examination, 25
indications, 23
insemination technique
fresh semen AI, 28
natural breeding, 27–28
surgical intrauterine insemination, 28–29
transcervical (intrauterine) insemination (TCI), 28
medical history, 24–25
ovulation timing and, 23
LH testing, 27
physiology, 25–26
serum progesterone concentration, 26–27
vaginal cytology, 26
vaginoscopy, 26
procedures, 24–25
recommendations, 30–31
semen handling considerations, 29–30
breeding management, of queen, 33–40
clinical features, 33–36
course and prognosis, 39
diagnostics, 36–38
differential diagnosis, 36
estrous cycle in cat, 34
etiology/pathophysiology, 33–35
penile spines and testosterone, 34
risk factors/problems, 35
signalment/history, 35
therapeutics, 38–39
bromocriptine, 145, 346, 368, 371
Brucella canis, 12, 449
brucellosis, canine, 449–454
client education, 454
clinical features, 450–451
course and prognosis, 454
definition, 449
diagnostics
imaging studies, 452
lab testing, 451
organism isolation, 452
pathologic findings, 452
serologic testing, 451–452
differential diagnosis, 451
historic findings, 450
patient monitoring, 454
risk factors, 450
systems affected, 449–450
therapeutics
alternative options, 453
drugs, 452–453
environmental control, 454
precautions/interactions, 453
prevention, 453–454
surgical considerations, 453
cabergoline, 145, 333, 342, 346, 368, 372–374
calcium acetate, 299
calcium carbonate, 299
calcium citrate, 299
calcium gluconate, 299
calcium lactate, 299
canine diabetes mellitus, 79–88
clinical features, 80–81
complications
cataract formation, 87
exocrine pancreatic insufficiency, 87
course and prognosis, 88
definition, 79
diabetic cataract, 80–81
differential diagnosis, 81
etiology/pathophysiology, 79–80
historic findings, 80
laboratory tests/imaging, 81–82
pathologic findings, 82
patient monitoring, 86–87
prevention/avoidance, 87
risk factors, 80
systems affected, 80
therapeutics, 82
activity, 85
client education, 86
diet, 84–85
drugs, 82–83
health care recommendations, 84
nursing care, 84
precautions/interactions, 83
surgical considerations, 85
Canine Eye Registry Foundation (CERF), 151
Canine Health Information Center (CHIC), 149
Canine Health Information Network (CHIC), 152
canine herpesvirus type 1 (CHV-1), see herpes virus, canine
canine hyperadrenocorticism (HAC), 159–177
adrenal biopsy, 168
associated conditions, 176
causes, 163
client education, 168
clinical features, 161–162
calcinosis cutis, 163
cutaneous hyperpigmentation, 162
hair loss, 161
thin skin, 162
complications, 176
course and prognosis, 176
definition, 159
diagnosis/differential diagnosis, 163–167
diet, 168
differentiating tests
endogenous ACTH concentration, 167
high-dose dexamethasone suppression test (HDSST), 167

drugs
  alternative drugs, 175
  contraindications, 175
  ketoconazole, 175
  L-deprenyl, 173
  mitotane, 169, 171–172
  precautions, 175
  trilostane, 170, 173–174

etiology/pathophysiology, 159–160

health care, 168

iatrogenic, 159

imaging studies, 167

laboratory tests, 164

nursing care, 168

pathologic findings, 168

patient monitoring, 175–176

pituitary-dependent HAC, 160

prevention/avoidance, 176

risk factors, 163

screening tests
  ACTH stimulation test, 166–167
  low-dose dexamethasone suppression test (LDDST), 164–166
  urine cortisol:creatinine ratio (UC:Cr), 164

signalment/history, 160

spontaneous, 159

surgical considerations, 169

etiology/pathophysiology, 543–548

definition, 543

etiology/pathophysiology, 543

signalment/history, 544

etiology/pathophysiology, 263–271

associated conditions, 270

atypical, 263

causes, 265

client education, 268

clinical features, 265

complications, 270

course and prognosis, 270

definition, 263

differential diagnosis, 265

etiology/pathophysiology, 263–264

therapeutics activity, 267

drugs, 268–269

health care, 267

nursing care, 267

canine hypothyroidism, 309–315

client education, 547

clinical features, 310–311, 545

course and prognosis, 315

definition, 309

diagnostics, 311–314, 546

breed difference and, 313

drugs effect, 314

laboratory diagnosis, 311–312

non-thyroidal illness, 314

pathological findings, 314

serum free T4, 312

serum total T3, 312

serum total T4, 312

serum TSH, 312

thyroid gland ultrasound, 314

thyroiditis, 313

TSH response test, 313

differential diagnosis, 310, 546

etiology/pathophysiology, 309

historic findings, 310

patient monitoring, 547

physical examination findings, 545

prevention/avoidance, 548

primary, 309

risk factors, 544

secondary form, 309

signalment/history, 310

systems affected, 309–310

therapeutics, 314–315, 547

canine minute virus (CnMV), 455–456

clinical features, 453–456

definition, 453

diagnostics, 456

differential diagnosis, 456

etiology/pathophysiology, 455

historic findings, 455

patient monitoring, 547

physical examination findings, 545

prevention/avoidance, 548

risk factors, 455

therapeutics, 456

canine parvovirus type 1 (CPV-1), see canine minute virus (CnMV)

canine prostate disease, 483–489

benign prostatic hypertrophy, 483

clinical features, 485

course and prognosis, 489

cystic benign prostatic hyperplasia, 483

definition, 483

diagnostics, 485–488

fine-needle aspiration, 487
canine prostate disease (continued)
fluid evaluation, 487
prostatic biopsy, 488
prostatic wash/massage, 487
radiography, 485
ultrasonography, 485–487
etiology/pathophysiology, 483
historic findings, 484–485
pathological findings, 488
prostatitis, 483
risk factors, 484
signalment/history, 484–485
systems affected, 484
therapeutics, 488–489
canine serum pancreatic lipase immunoreactivity (cPLI), 82
canine transmissible venereal tumor (TVT), 491–494
clinical features, 492
definition, 491
diagnostics, 492–493
differential diagnosis, 492
etiology/pathophysiology, 491
prevention, 494
prognosis, 494
signalment/history, 492
systems affected, 491
therapeutics, 493–494
drugs, 494
precautions, 494
carbimazole, for hyperthyroidism in cat, 256
carboplatin, 503
carcinoids, 41–44
clinical features, 42
course and prognosis, 44
definition, 41
diagnostics
imaging, 43
laboratory tests, 42–43
pathologic findings, 43
differential diagnosis, 42
etiology/pathophysiology, 41–42
patient monitoring, 44
signalment/history, 42
therapeutics, 43
carcinoid syndrome, human, 41–42
celiotomy, 48
central diabetes insipidus (CDI), 73. See also diabetes insipidus (DI)
cephalosporins, 421
cesarean section (CS), 43–51
body temperature, neonate, 50
complications and follow-up, 50
definition, 43
equipment, 47
heart rate, neonate, 50
indications for
acute CS, 45–46
elective CS, 46
patient anesthesia and analgesia, 47–48
preoperative steps, 47
respiratory rate, neonate, 50
signalment/history, 47
surgical procedure, 48–50
timing of, 46
chlorpropamide, 77
chronic kidney disease, in cats, 253
chylomicron test, 201
cisplatin, 503
clofibrate, 503
cloprostenol, 367, 374, 421
and bromocriptine, 371
and cabergoline, 370–371
colostrum, 391
Companion Animal Parasite Council (CAPC), 1, 10
congenital disorder, 147
Conn's syndrome, see primary hyperaldosteronism (PHA), in cats
cranial diabetes insipidus, see diabetes insipidus (DI)
cretinism, 543–548
cryptorchidism, 63–70
bilateral, 63
clinical features, 64
conditions associated with, 70
definition, 63
diagnosis, 64–65
differential diagnosis, 65
imaging, 66–69
canine benign prostatic hyperplasia, 68
canine cryptorchid, abdominal testis, 67
canine intra-abdominal testicular torsion, 69
feline cryptorchid, abdominal testis, 68
sertoli cell tumor, 69
laboratory tests, 66
with persistent Müllerian duct syndrome, 63
signalment/history, 63–64
therapeutics, 70
follow-up, 70
hCG injections in dogs, 70
unilateral, 63
cryptosporidium, canine, 441–444
client education, 444
clinical features, 442
course and prognosis, 444
definition, 441
diagnostics, 443
differential diagnosis, 443
etiology/pathophysiology, 441–442
historic findings, 442
pathological findings, 443
patient monitoring, 443
prevention/avoidance, 444
risk factors, 442
systems affected, 442
therapeutics
drugs, 443
nursing care, 443
precautions/interactions, 443
Cushing's disease, see hyperadrenocorticism (HAC)
Cushing's syndrome, see hyperadrenocorticism (HAC)
cystic benign prostatic hyperplasia (CBPH), 483. See also
canine prostate disease
cystic endometrial hyperplasia (CEH), 53

DDAVP (desmopressin), 75–76, 241
delayed puberty, 139–140. See also estrous cycle
abnormalities
deoxy corticosterone pivalate, 275
in autoimmune polyglandular syndrome, 19
deracoxib, 303
deslorelin, 347, 351
dexamethasone, 369–370, 374
diabetes insipidus (DI), 73–78
ADH supplementation trial, 75
age-related factors, 77
causes, 74
central, 73
clinical features, 74
complications, 77
course and prognosis, 77
definition, 73
diagnostics, 75
differential diagnosis, 74
etiology/pathophysiology, 73
imaging, 75
laboratory tests, 74
nephrogenic, 73
pathologic findings, 75
signalment/history, 73
systems affected, 73
therapeutics, 76
client education, 76
drugs, 76–77
patient monitoring, 77
precautions, 76
prevention/avoidance, 77
diabetes mellitus with hyperosmolar coma, 211–217
associated conditions, 216
causes, 212
client education, 216
clinical features, 212–213
complications, 216
course and prognosis, 216
definition, 211
differential diagnosis, 213
etiology/pathophysiology, 211
historic findings, 212
laboratory tests, 213
pathologic findings, 214
patient monitoring, 215–216
physical examination findings, 212
risk factors, 213
signalment/history, 212
systems affected, 211
therapeutics
diet, 214
drugs, 214–215
health care, 214
nursing care, 214
precautions, 215
diabetic coma, see diabetes mellitus with hyperosmolar
coma
diabetic dermatopathy, 154
diabetic ketoacidosis, in cats and dogs, 99–106
causes, 101
clinical features, 100
complications, 105
conditions associated with, 105
course and prognosis, 105
definition, 99
diagnostic procedures, 102
differential diagnosis, 101
drugs, 103–105
bicarbonate supplementation, 104
dextrose supplementation, 104
insulin, 103
phosphorus supplementation, 104
potassium supplementation, 103–104
etiology/pathophysiology, 99
laboratory tests, 101–102
pathologic findings, 102
patient monitoring, 105
risk factors, 101
signalment/history, 100
systems affected, 99
therapeutics
client education, 103
diet, 102
health care, 102
nursing care, 102
diabetic neuropathy, cat, 91
diazoxide, 322
dihydrostreptomycin, 453
dihydrotachysterol, 299
1,25-dihydroxycholecalciferol, 299
dinoprost tromethamine, 371
disorders of sexual differentiation (DSD), 109–116
age-related factors, 115
causes, 113
client education, 114
complications, 115
contraindications, 115
definition, 109
disorders of sexual differentiation (DSD) (continued)
etiology/pathophysiology, 109–111
genetics, 111
histopathologic examination, 114
historic findings, 112
imaging studies, 114
incidence/prevalence, 111
laboratory tests, 113
pathologic findings, 114
patient monitoring, 115
physical examination findings, 112–113
risk factors, 113
sex chromosome DSD, 109–110
signalment/history, 112
surgical considerations, 115
systems affected, 111
therapeutics
health care, 114
nursing care, 114
XX DSD, 110–111
XY DSD, 110
DNA (genotypic) test, 147
dogs
acromegaly in, 231. See also hyposomatotropism (HS), in dog
cryptorchid, 63. See also cryptorchidism
diabetic, see canine diabetes mellitus
hyperlipidemia in, 197. See also hyperlipidemia
hyperthyroidism in, 245
parasitic infection in, 1–10
primary carcinoid tumors in, 41. See also carcinoids
domperidone, 333
dopaminergics, for medical abortion, 368
doxorubicin, 494
dystocia, 117–125
and cesarean section, 45–46
definition, 117
diagnostics, 123–125
external monitoring devices, use of, 123–124
fetal heart rates, 124–125
physical examination, 123
serial tocodynamometry in bitch and queen, 124
etiology/pathophysiology, 120–122
anasarca, 120, 122
fetal factors, 120, 122
fetal malposition, 120
uterine inertia, 120–121
gestation, 117
in bitch, 117–118
in queen, 118
stages of labor
in bitch, 118, 120
in queen, 120
therapeutics, 125
calcium administration, 125
cesarean section, 125
medical therapy, 125
oxytocin administration, 125
eCG, 348
eclampsia, 127–30
clinical features, 128
course and prognosis, 130
definition, 127
diagnostics, 128
differential diagnosis, 128
etiology/pathophysiology, 127
historic findings, 128
risk factors, 128
signalment/history, 127–128
systems affected, 127
with tetany, 129
therapeutics, 129
drugs, 129
procedures, 129–130
without tetany, 129
ectoparasites, 1. See also parasitic infection
edema, in canine pregnancy, see pregnancy edema, in bitch
en-bloc surgery, 50
endocrine testing, 201
endoscopy, 401
enrofloxacin, 453
epididymitis, 509. See also semen abnormalities, canine
episioplasty, 131–137
clinical features, 132
clinical signs, 132
definition, 131
diagnostics, 133
retraction of skin fold, 133–134
differential diagnosis, 133
etiology/pathophysiology, 132
historic findings, 132
perivulvar dermatitis and, 131, 134–135, 137
risk factors, 132–133
signalment/history, 132
therapeutics, 135
bitch post episioplasty, 137
completed episioplasty, 136
recessed/hooded vulva prior to episioplasty, 135
urinary tract infections and, 131, 137
ergocalciferol, 299
Escherichia coli infection, queen, 461
esmolol, 414
estriadiol benzoate, 366
estradiol cypionate, 366
estrogens, for mismate, 365
estrous cycle abnormalities, 139–146
clinical features, 141–142
course and prognosis, 145–146
definition/overview, 139–140
prolonged anestrus, 139
prolonged proestrus/estrus, 139
shortened interestrous interval (IEI), 139
silent heat, 139
diagnostics, 142–143
ultrasound, 142
etiology/pathophysiology, 140–141
pathological findings, 143–144
luteomas, 143–144
signalment/history, 141
systems affected, 141
therapeutics, 144–145
estrous cycles, medical manipulation of, 345–354
definition, 345
estrous cycle, prevention of
in bitches, 348–351
in queens, 352–353
shortening of long interestrous interval (IEI)
in bitches, 345–347
in queens, 347–348
therapeutics
drugs, 346–347
precautions/interactions, 346–347
euthyroid sick syndrome, 314
exocrine pancreatic insufficiency (EPI), 79, 87
fading puppy syndrome, see herpes virus, canine
fasting triglycerides, 201
Feline Advisory Bureau (FAB-UK), 149
feline diabetes mellitus, 89–98
client education, 95
clinical features, 91
complications, 97
course and prognosis, 97
definition, 89
and diabetic neuropathy, 91
diagnostics, 92
differential diagnosis, 91
etiology/pathophysiology, 89–90
glycosuria and, 92
historic findings, 90
obesity and, 89, 97
patient monitoring
blood glucose curves, 95–96
continuous glucose monitors, 96
fructosamine concentrations, 96–97
urinary glucose monitoring, 95
prevention/avoidance, 97
risk factors, 90
signalment/history, 90
stress-related hyperglycemia and, 92
systems affected, 90
therapeutics, 92
activity, 94
diet, 94
drugs, 92–93
health care, 93
nursing care, 93
precautions/interactions, 93
surgical considerations, 94
type 2 DM, 89
feline herpesvirus (FHV), 461
feline hyperadrenocorticism, 179–183
clinical features, 180–181
definition, 179
differential diagnosis, 181
endocrine testing, 181–182
etiology/pathophysiology, 179
functional adrenal tumor (FAT), 179
imaging studies, 182
laboratory testing, 181
pituitary-dependent, 179
signalment/history, 180
therapeutics, 182
feline hyperthyroidism, 243–262. See also hyperthyroidism
feline hypoadrenocorticism, 273–276
clinical features, 274
course and prognosis, 275
definition, 273
differential diagnosis, 274
etiology/pathophysiology, 273
laboratory tests, 274–275
pathological findings, 275
primary, 273
secondary, 273
signalment/history, 273–274
systems affected, 273
therapeutics, 275
feline hypothyroidism, 543–548
client education, 547
clinical features, 544–545
course and prognosis, 548
definition, 543
diagnostics, 546
differential diagnosis, 545
etiology/pathophysiology, 543
patient monitoring, 547
physical examination findings, 545
prevention/avoidance, 547
risk factors, 544
signalment/history, 544
therapeutics, 547
feline immunodeficiency virus (FIV), 461–462
feline leukemia virus (FeLV), 462
feline mammary hyperplasia (FMH), 337–342
clinical features, 339–340
course and prognosis, 342
definition, 337
diagnostics, 340
therapeutics, 340
cytologic examination, 340
pathological findings, 340
feline mammary hyperplasia (FMH) (continued)
differential diagnosis, 340
etiology/pathophysiology, 337–338
historic findings, 338
risk factors, 338
signalment/history, 338–339
systems affected, 337
therapeutics, 341–342
drugs, 342
medical, 341–342
surgery, 341
feline panleukopenia virus (FPV), 461
feminizing paraneoplastic syndrome, 64
fetal distress, 124
fetal Doppler monitoring, 124
fetal hypoxia, 47
finasteride, 488
fludrocortisone acetate, 268
fludrocortisone suppression test, 479
fluprostopenol, 367
fructosamine, 87, 96–97
furosemide, 429–430
galactostasis, 325–336
clinical features, 329
definition, 325
diagnostics, 331
differential diagnosis, 331
etiology/pathophysiology, 326
historic findings, 328
pathological findings, 331
risk factors, 327–328
signalment/history, 327
systems affected, 326
therapeutics, 333
Galastop®, 333
gemcitabine, 503
genetic disease counseling
equipment, 149
indications, 148–149
in pre-breeding examination, 147–152
procedure, 149–151
terminology related to, 147–148
genotype, 147
gentamicin, 453
gestation
in bitch, 117–118
prolonged, see dystocia
in queen, 118
gestational aging, ultrasonographic, 537–542
biparietal diameter (BP) and, 537, 541
crown–rump length (CRL) and, 538–539, 541
equipment, 537
indications, 537
inner chorionic cavity (ICC) and, 537–538, 541
procedures, 537–538
advanced pregnancy, 539–540
eyear pregnancy, 538–539
results and difficulties, 541
gestational diabetes, see pregnancy diabetes
GH-induced insulin-like growth factor-1 (IGF-1), 231, 235
Giardia infection, in dogs, 2
GIP (glucose-dependent insulinotropic peptide), 89
glargin insulin, 83, 93, 424
GLP-1 (glucagon-like peptide-1), 89
glucagon, 322
glucagonoma, 153–157
clinical features, 154
contraindications, 157
course and prognosis, 157
definition, 153
differential diagnosis, 154–155
etiology/pathophysiology, 153
historic findings, 154
imaging studies, 155
laboratory tests, 155
pathologic finding, 155–156
patient monitoring, 156–157
signalment/history, 154
systems affected, 154
therapeutics, 156
alternative treatments, 156
drugs, 156
surgical treatment, 156
glucocorticoid (cortisol) deficiency, 263
glucocorticoid replacement, 268
GnRH agonists, 347, 351–353
GnRH and hCG stimulation testing, 401
growth hormone (GH), 231, 235
hamburger toxicosis, 543–548
heartworm (Dirofilaria immitis), 1
hematometra, 53–62
clinical features, 55
definition, 53
diagnostics, 55–57
culture and sensitivity, 56
laboratory tests, 55
pathological findings, 57
radiography, 56
ultrasonography, 56–57
etiology/pathophysiology, 53–54
historic findings, 54
risk factors, 54
signalment/history, 54
systems affected, 54
therapeutics, 57–60
drugs, 59–60
medical treatment, 59
procedures, 61
supportive care, 59
hepatic arterial chemoembolization, 156
hepatocutaneous syndrome, 154
hereditary disorder, 147
hermaphrodites, see disorders of sexual differentiation (DSD)
herpes virus, canine, 444–449
  client education, 448
  clinical features, 445–446
  course and prognosis, 449
  definition, 444
  diagnostics
    antemortem testing, 446
    postmortem testing, 447
  differential diagnosis, 446
  etiology/pathophysiology, 445
  historic findings, 445
  pathological findings, 447
  prevention/avoidance, 448–449
  risk factors, 445
  systems affected, 445
  therapeutics
    diet, 448
    drugs, 447
    health care, 448
    nursing care, 448
    precautions/interactions, 447
    vaccination, 448–449
heterozygous, 147
high blood sugar, see hyperglycemia
high-dose dexamethasone suppression test (HDSST), 167, 181
homozygous, 147
hookworm infection, in dogs, 2. See also parasitic infection
hospital-generated serial blood glucose curves, 87
hydralazine, 429
hydrochlorothiazide, 76
hydrometra, 53–62
  clinical features, 55
  definition, 53
  diagnostics, 53–57
    culture and sensitivity, 56
    laboratory tests, 55
    pathological findings, 57
    radiography, 56
    ultrasonography, 56–57
  etiology/pathophysiology, 53–54
  historic findings, 54
  risk factors, 54
  signalment/history, 54
  systems affected, 54
  therapeutics, 57–60
    drug treatment, 59–60
    medical treatment, 59
  procedures, 61
  supportive care, 59
hyperadrenocorticism (HAC)
canine, 159–177
feline, 179–183
hypercalcemia of malignancy, 220
hyperestrogenism/estrogen toxicity, 395–406
  clinical features, 398
  course and prognosis, 406
  definition, 395
  diagnostics, 402–403
  differential diagnosis, 398–399
  etiology/pathophysiology, 395–396
  historic findings, 397
  patient monitoring, 405
  prevention/avoidance, 405
  risk factors, 397
  signalment/history, 396
  systems affected, 396
  therapeutics, 405
hyperglycemia, 183–190
  associated conditions, 189
  causes, 186
  clinical features, 186
  complications, 189
  definition, 185
  diet, 189
  differential diagnosis, 187
  etiology/pathophysiology, 185
  historic findings, 186
  laboratory tests, 187–188
  physical examination, 186
  risk factors, 187
  signalment/history, 185
  systems affected, 185
  therapeutics, 188–189
    acarbose, 189
    insulin therapy, 188
    patient monitoring, 189
hyperinsulinism, see insulinoma
hyperkalemia, 191–195, 263
  clinical features, 192
  complications, 194
  course and prognosis, 194
  definition, 191
  diagnostics
    electrocardiogram, 193
    imaging studies, 193
    laboratory tests, 192–193
  differential diagnosis, 192
  etiology/pathophysiology, 191
  patient monitoring, 194
  prevention/avoidance, 194
  risk factors, 191
  systems affected, 191
  therapeutics, 193–194
    drug therapy, 193, 194
    precautions/interactions, 193
hyperlipidemia, 197–203
  clinical features, 199–200
  complications, 202
hyperlipidemia (continued)
course and prognosis, 203
definition, 197
differential diagnosis, 200
etiology/pathophysiology, 197–198
historic findings, 199
laboratory tests, 200–202
primary, 197–198
risk factors, 199
secondary, 198
signalment/history, 199
systems affected, 198
therapeutics
dietary management, 202
drugs, 202
hypernatremia, 205–209
causes, 206
clinical features, 205–206
complications, 208
definition, 205
differential diagnosis, 206
imaging studies, 207
laboratory tests, 206–207
medication, 207–208
pathophysiology, 205
patient monitoring, 208
signalment, 205
systems affected, 205
treatment, 207
hyperosmolar coma, see diabetes mellitus with hyperosmolar coma
hyperparathyroidism, 219–223
clinical pathology, 220
complications, 223
course and prognosis, 223
definition, 219
differential diagnosis, 220
endocrine diagnostics, 221
etiology/pathophysiology, 219
historic findings, 219–220
and hypercalcemia, 219
imaging studies, 221
nutritional secondary, 227
pathological findings, 221
patient monitoring, 222
physical examination, 220
risk factors, 219
signalment/history, 219
systems affected, 219
therapeutics
activity, 222
diet, 222
drugs, 221
nursing care, 222
surgical considerations, 222
hyperphosphatemia, 225–230
acute, 225
age-related factors, 229
causes, 226
chronic, 226
clinical features, 225–226
complications, 229
definition, 225
differential diagnosis, 226–227
etiology/pathophysiology, 225
historic findings, 225
imaging studies, 228
laboratory tests, 227–228
patient monitoring, 229
physical examination findings, 226
renal biopsy, 228
risk factors, 226
signalment/history, 225
therapeutics, 228–229
drugs, 228
hypersomatotropism (HS), in cat, 235–243
acromegaly induced by, 235
clinical features, 238–239
facial features, 238–239
course and prognosis, 243–244
definition, 235
and diabetes mellitus, 235–236
diagnostics, 240
differential diagnosis, 239
etiology/pathophysiology, 235–236
pathological findings, 241
signalment/history, 237–238
systems affected, 236–237
therapeutics, 241–242
drugs, 241
palliative treatment, 242
radiotherapy, 241–242
surgery, 241
hypersomatotropism (HS), in dog, 231–234
acromegaly induced by, 231
clinical features, 232
course and prognosis, 233
definition, 231
diagnostics, 233
differential diagnosis, 232–233
etiology/pathophysiology, 231
historic findings, 232
pathological findings, 233
physical examination, 232
risk factors, 232
systems affected, 231–232
therapeutics, 233
drugs, 233
radiotherapy, 233
surgery, 233
hypothyroidism, 245
  in cats, 227, 245–262
  clinical features, 247
concurrent non-thyroidal conditions
  chronic kidney disease, 233
  hepatic disease, 255
  secondary hypertension, 254–255
  thyrotoxic heart disease, 254
course and prognosis, 261
definition, 245
diagnostics, 248
  abdominal ultrasound, 250
  chest radiography, 250
  echocardiography, 250
  hematological findings, 249
  pathologic findings, 253
  serum chemistry profile, 249
  thyroid function tests, 251–253
  thyroid nodule, palpation of, 248–249
  thyroid scintigraphy, 250–251
  urinalysis, 249–250
differential diagnosis, 247–248
etiology/pathophysiology, 245–246
historic findings, 246–247
medical management, 255
  advantages and disadvantages, 255
  antithyroid drugs, 255–257
  carbimazole, 256
  indications, 255
  methimazole, 255
nutritional therapy, 257–258
overview, 245
radioactive iodine therapy, 259–261
risk factors, 246
signalment/history, 246–247
systems affected, 245–246
thyroidectomy, 238–259
thyroid gland lesions and, 245
treatment, 253–261. See also specific treatment
  advantages and disadvantages, 254
hypoadrenocorticism, 263
canine, 17–18, 263–271. See also autoimmune polyglandular syndromes (APSs)
feline, 273–276
hypocalcemia, 127. See also eclampsia
hypoglycemia, 277–280
  activity, 280
  clinical features, 278
  definition, 277
diagnostics, 278–279
diet, 280
differential diagnosis, 278
drug therapy, 279
etiology/pathophysiology, 277
imaging studies, 279
nursing care, 280
signalment/history, 277–278
systems affected, 277
hypoglycemia, in dog, 83, 86
hypokalemia, 281–287
  associated conditions, 286
  causes
    decreased intake, 282
    gastrointestinal loss, 282
    translocation, 282–283
    urinary loss, 282
  clinical features, 282
  complications, 286
definition, 281
diagnostics, 283–284
differential diagnosis, 283
etiology/pathophysiology, 281
imaging studies, 284
laboratory tests, 283–284
medications, 284–285
patient monitoring, 286
risk factors, 283
signalment/history, 281
systems affected, 281
therapeutics, 284–286
hypokalemic nephropathy, 477
hyponatremia, 289–293
  causes, 290
  client education, 293
  clinical features, 290
  complications, 293
course and prognosis, 293
definition, 289
differential diagnosis, 291
etiology/pathophysiology, 289
hyperosmolar, 290
hypoosmolar, 290
laboratory tests, 291
patient monitoring, 292
prevention/avoidance, 292
signalment/history, 289
systems affected, 289
therapeutics, 292
  drugs, 292
  precautions, 292
hypoparathyroidism, 226, 295–301
  client education, 300
  clinical features, 296
  complications, 301
course and prognosis, 301
definition, 295
diagnostics, 297–298
differential diagnosis
  muscle tremors, 297
hypoparathyroidism (continued)
  muscle weakness, 297
  seizures, 297
etiology/pathophysiology, 295
historic findings, 296
pathologic findings, 298
patient monitoring, 300
prevention/avoidance, 300
signalment/history, 295–296
systems affected, 295
therapeutics, 298–300
diet, 300
drugs, 298–300
nursing care, 300
hypophosphatemia, 303–308
age-related factors, 307
associated conditions, 307
causes, 304
definition, 303
differential diagnosis, 305
etiology/pathophysiology, 303–304
historic findings, 304
imaging studies, 305
laboratory tests, 305
physical examination findings, 304
risk factors, 304
signalment/history, 304
systems affected, 304–305
therapeutics, 306
drugs, 306–307
follow-up, 307
patient monitoring, 307
hypophysectomy, 241
hypothyroidism, in dog, 17–18. See also autoimmune polyglandular syndromes (APSs)

incretin, 90
infection, and pregnancy loss
canine, 437–456
feline, 459–465
infectious diseases, in breeding dogs and bitches, 13
infertility, in bitch, 12
insulin-dependent diabetes mellitus (IDDM), in dog, 17–18. See also autoimmune polyglandular syndromes (APSs)
inulin dosing pens, 83, 93
insulin-induced hypoglycemia, 83, 93
insulinoma, 278–279, 317–323
age-related factors, 323
associated conditions, 323
causes, 318
clinical features, 318–319
course and prognosis, 323
definition, 317
differential diagnosis, 319
etiology/pathophysiology, 317
exploratory laparotomy, 320
historic findings, 318
imaging studies, 320
laboratory tests, 319
pathologic findings, 320
patient monitoring, 322
physical examination findings, 318
risk factors, 319
signalment/history, 317–318
systems affected, 317
therapeutics
  client education, 321
  complications, 322
diet, 321
health care, 320
medications, 321–322
nursing care, 320
possible interactions, 322
precautions, 322
surgical considerations, 321
insulin-producing pancreatic tumor, see insulinoma
insulin-secret ing tumor, see insulinoma
interrestrus interval (IEI), 338
intersex, see disorders of sexual differentiation (DSD)
testinal parasites, 1–2. See also parasitic infection
Islet cell adenocarcinoma, see insulinoma
Islet cell tumor, see insulinoma
isosphane/neutral protamine hagedorn (NPH) insulin, 83
jasmine toxicity, 227
kayexalate, 193
ketonconazole, for hyperad renocortic ism in dogs, 175
Klinefelter syndrome, see disorders of sexual differentiation (DSD)
lactescence, 197
lactoterrin, 447
lantreotide, 322
lasix, 221
L-deprenyl, for pituitary-dependent hyperadrenocercism, 173
lente insulin, 83, 92
levothyroxine
  for autoimmune polyglandular syndrome, 19
  for hypothyroidism, 314–315
lipemia, 197
lipoprotein electrophoresis, 202
lispro insulin, 82
low-dose dexamethasone suppression test (LDDST), 164–166, 181
low-renin hyperaldosteronism, see primary hyperaldosteronism (PHA), in cats
luteinizing hormone (LH), 66
testing, 400
luteolytics, for medical abortion
in bitch, 366–368
in queen, 372–373
magnesium sulfate, 429
male pseudohermaphroditism, 63
mammary gland disorders, see agalactia; galactostasis; mastitis
mastectomy, 341
mastitis, 325–336
clinical features, 329–330
acute, 330
chronic/subclinical, 330
definition, 325
diagnostics, 331
differential diagnosis, 331
erthemic nodule, 330
etiology/pathophysiology, 326
historic findings, 329
necrosis/gangrene in, 334
with nursing offspring, 335
pathological findings, 331
prevention, 336
risk factors, 327–328
signalment/history, 327
systems affected, 326
therapeutics, 334–336
without nursing offspring, 335
medical abortion, canine and feline, 357–375
clinical features, 359
course and prognosis, 375
definition, 357
diagnostics
palpation, 362
pregnancy tests, 361
progesterone testing, 361
radiographs, 363
ultrasound, 362–363
vaginal cytology, 360–361
differential diagnosis
observed mating, 359
pregnancy, 360
pseudopregnancy, 360
suspected mating, 359–360
vaginal discharge, 360
drugs for, 373–374
bitch, 365–372
queen, 372–373
etiology/pathophysiology, 357–358
objective of, 363
post abortion ultrasound, 363–364
signalment/history, 358–359
medroxyprogesterone acetate (MPA), 349
metabolic epidermal necrosis, 154
metergoline, 368
methimazole, for hyperthyroidism in cat, 255
methyprednisolone acetate, 275
metoclopramide, 333, 430
mibolerone, 145, 349–350
mineralocorticoid (aldosterone) deficiency, 263
mineralocorticoid replacement (DOCP), 268–269
misoprostol, 371–372
mitotane
for adrenal tumor, 170–172
for pituitary-dependent hyperadrenocorticism, 169–172
mitoxantrone, 503
mode of inheritance, 147
autosomal, 147
co-dominant, 148
dominant, 148
epistasis, 148
monogenic, 148
multi-factorial, 148
polygenic, 148
recessive, 148
sex-linked, 148
modified water-deprivation test, 75
mucometra, 53–62
clinical features, 55
definition, 53
diagnostics, 55–57
culture and sensitivity, 56
laboratory tests, 55
pathological findings, 57
radiography, 56
ultrasonography, 56, 57
etiology/pathophysiology, 53–54
historic findings, 54
risk factors, 54
signalment/history, 54
systems affected, 54
therapeutics, 57–60
drug treatment, 59–60
medical treatment, 59
ovariohysterectomy, 57–58
procedures, 61
supportive care, 59
necrolytic migratory erythema (NME), 153–154. See also glucagonoma
neonatal herpes, see herpes virus, canine
neonatal isoerythrolysis (NI), in kittens, 378, 385
neonatal resuscitation and neonatal care, 377–387
client education, 386
clinical signs, 379
compromised puppies and kittens, 379
normal puppies and kittens, 379
definition, 377
equipment, 380
etiology/pathophysiology, 377
fluid therapy, 385–386
incidence/prevalence, 378
neonatal resuscitation and neonatal care (continued)
low-weight puppies/kittens, 378
neonate examination, 386
respiratory depression and action, 381–386
risk factors, 377–378
suckle reflex in neonate, 379
therapeutics, 381–386
umbilicus 24 hours post-partum, 387
Neospora caninum, 437. See also toxoplasmosis/
neosporosis, canine
nephrogenic diabetes insipidus, see diabetes insipidus
(DI)
nephrogenic diabetes insipidus (NDI), 73. See also
diabetes insipidus (DI)
nitazoxanide (NTZ), 443
non-azotemia tumoral calcinosis, 227
NSAIDs, for prostatic carcinomas, 503
nutritional secondary hyperparathyroidism, 227
nutrition, in pregnancy and lactation, 389–393
carbohydrate and, 392
clinical features, 391
commercially available diets, 391
definition, 389
diagnostics, 392
energy requirements and, 389
etiology/pathophysiology, 389–390
fat and, 392
goals of feeding, 389
hypocalcemia risk and, 390
protein and, 392
signalment/history, 390
vitamins and minerals, 392
octreotide, 43, 156, 322
Ohio State University (OSU) Reference Laboratory, 479
orchitis, 509. See also semen abnormalities, canine
Orthopedic Foundation for Animals (OFA), 151
ovarian differentiation, 109. See also disorders of sexual
differentiation (DSD)
ovarian remnant syndrome (ORS), 66, 395–406
clinical features
canine, 397
feline, 398
course and prognosis, 406
definition, 395
diagnostics, 399–402
differential diagnosis
attractive to male dogs, 398–399
infertility, 399
non-pruritic, symmetric alopecia, 398
etiologic/pathophysiologic, 395–396
historic findings, 397
patient monitoring, 405
prevention/avoidance, 405
risk factors, 397
signalment/history, 396
systems affected, 396
therapeutics, 404
ovariectomy, 341
ovariohysterectomy, 50, 57, 424, 435, 514, 555
ovaric pseudopregnancy, 360
ovulation, evaluation of, with ultrasound, 529–534
course and prognosis, 534
difficult cases, 534
equipment, 529
indications, 529
procedure, 529
ovaries, location of, 531
ovulation, 532–533
positioning, 529–530
post-ovulatory period, 532–533
pre-ovulatory period, 531–532
start of pro-estrus, 531
ovulation timing (OT), 23. See also breeding management,
of bitch
oxytocin, 421
in dystocia, 125
for uterine inertia, 526–527
paraneoplastic hypoglycemia, 319
paraphimosis, 467–475
clinical features, 471
definition, 467–468
diagnostics, 472–473
differential diagnosis, 471–472
etiology/pathophysiology, 470–471
systems affected, 471
therapeutics, 474–475
parasitic infection
clinical features, 2
diagnostics, 3
differential diagnosis, 3
etiology/pathophysiology, 1–2
historic findings, 2
parasite preventive charts, 4–9
in pregnant and breeding dogs, 1–10
signalment/history, 2
therapeutics, 3–9
paromomycin, 443
Pasireotide®, 241
perivulvar dermatitis, 131. See also episiotomy
persistent Mullerian duct syndrome (PMDS), 63–64
phenotype, 148
phenotypic sex differentiation, 109. See also disorders of
sexual differentiation (DSD)
phenotypic test, 148
phenolamine, 414
phenolamine test, 412–413
pheochromocytoma, 409–415
  associated conditions, 414
  clinical features, 410–411
  complications, 414
  course and prognosis, 414
  definition, 409
  diagnostic procedures, 412–413
  differential diagnosis, 411
  etiology/pathophysiology, 409
  historic findings, 410
  imaging studies
    abdominal radiography, 411–412
    abdominal ultrasonography, 412
    thoracic radiography, 412
  laboratory tests, 411
  pathologic findings, 413
  patient monitoring, 414
  physical examination findings, 410–411
  signalment/history, 409–411
  therapeutics
    client education, 413
    health care, 413
    medications, 414
    surgical considerations, 413
  phosphorus, 303. See also hypophosphatemia
  phosphate binders, 228
  piroxicam, 503
  pituitary adenomas, 231
  pituitary-dependent hyperadrenocorticism (PDH), 160.
    See also canine hyperadrenocorticism (HAC); feline hyperadrenocorticism
  polybrominated diphenyl ethers (PBDEs), 246
  polyendocrine gland failure, see autoimmune polyglandular syndromes (APSs)
  post-partum metritis, 417–422
    clinical features, 419
    course and prognosis, 422
    definition, 417
    diagnostics, 419–421
    differential diagnosis, 419
    etiology/pathophysiology, 417
    historic findings, 418
    pathologic findings, 421
    risk factors, 418
    signalment/history, 418
    systems affected, 417–418
    therapeutics, 421–422
  postparturient hypocalcemia, see eclampsia
  potassium, 191, 281. See also hyperkalemia; hypokalemia
  potassium phosphate, 306
  pregnancy diabetes, 423–425
    clinical features, 423–424
    complications, 425
    course and prognosis, 425
    definition, 423
    diagnostics, 424
    differential diagnosis, 424
    etiology/pathophysiology, 423
    signalment/history, 423
    surgical considerations, 424
    therapeutics, 424
  pregnancy edema, in bitch, 427–431
    client education, 431
    clinical features, 428
    complications, 431
    course and prognosis, 431
    definition, 427
    diagnostics, 429
    differential diagnosis, 428
    etiology/pathophysiology, 427
    historic findings, 428
    pathologic findings, 429
    patient monitoring, 431
    prevention/avoidance, 431
    risk factors, 428
    signalment/history, 428
    systems affected, 427–428
    therapeutics, 429
      diet, 430
      drugs, 429–430
      health care, 430
      nursing care, 430
      precautions/interactions, 430
      surgical considerations, 430–431
  pregnancy ketosis, 433–435
    clinical features, 434
    definition, 433
    diagnostics, 434
    differential diagnosis, 434
    etiology/pathophysiology, 433
    risk factors, 433–434
    signalment/history, 433
    surgical considerations, 433
    systems affected, 433
    therapeutics, 435
      diet, 430
      drugs, 429–430
      health care, 430
      nursing care, 430
      precautions/interactions, 430
      surgical considerations, 430–431
  pregnancy loss in canine, infection and, 437–456
    brucellosis, 449–454
    cryptosporidium, 441–444
    herpes virus, 444–449
    minute virus, 455–456
    toxoplasmosis/neosporosis, 437–441
  pregnancy loss in feline, infection and, 459–465
    bacterial infections
      brucellosis, 460
      Escherichia coli, 461
      Salmonella, 461
      Streptococcus spp., 461
    course and prognosis, 465
    definition, 459
    diagnostics
      aerobic culture, 463
      antibody and antigen evaluation, 463
pregnancy loss in feline, infection and (continued)
clinical/anatomic pathology evaluation, 464
imaging studies, 464
laboratory tests, 463
PCR testing, 463
serum hormone evaluation, 463
differential diagnosis
dystocia, 463
failure to conceive, 462
maternal health, 462
trauma, 462
early pregnancy loss/resorption, 460
etiology/pathophysiology, 459–460
historic findings, 460
late pregnancy loss, 460
precautions/interactions, 464
prevention/avoidance, 465
protozoal infections
Toxoplasma gondii, 462
risk factors, 460
signalment/history, 460
systems affected, 460
therapeutics, 464
viral infections
feline herpesvirus, 461
feline immunodeficiency virus, 461–462
feline leukemia virus, 462
feline panleukopenia virus, 461
prerenal azotemia, 226
priapism, 467–475
clinical features, 471
definition, 467
diagnostics, 472–473
differential diagnosis, 471
etiology/pathophysiology, 469–470
ischemic, 467, 470, 474
non-ischemic, 467, 469–470
systems affected, 471
therapeutics, 474
primary hyperaldosteronism (PHA), in cats, 477–481
confirmatory tests for, 479–480
definition, 477
diagnostics, 480
etiology/pathophysiology, 477–478
historic findings, 478
laboratory abnormalities, 479
physical examination, 478–479
screening tests for, 479
signalment/history, 478–480
therapeutics
medical therapy, 480
prognosis, 481
surgery, 480
progesterone blockers, 368–369
progesterone in oil, 145
prolactin inhibitors, 368
proligestone (PROL), 349–350
Prometrium®, 145
prostaglandins, for medical abortion
in bitch, 366–367
in queen, 372–373
prostatic adenocarcinoma, canine, 504–507
clinical features, 505–506
definition, 504
diagnostics, 506
differential diagnosis, 506
etiology/pathophysiology, 505
historic findings, 505
pathological findings, 507
risk factors, 505
signalment/history, 505
systems affected, 505
therapeutics, 507
prostatic hyperplasia, in dog, 66
prostatic transitional cell carcinoma (TCC), 498–504
clinical features, 500
definition, 498–499
diagnostics, 500–502
differential diagnosis, 500
etiology/pathophysiology, 499
historic findings, 499–500
hydroureret and hydronephrosis with, 500–501
intraprostatic mineralization, 502
lymph node metastases, 499
pathological findings, 502
risk factors, 499
signalment, 499
sublumbar lymphadenopathy with, 500–501
systems affected, 499
therapeutics, 503
drugs, 503
precautions, 503–504
prostatitis (IP), 483. See also canine prostate disease
prostamine zinc insulin (PZI), 83, 93
protozoal infections, queen, 462
pseudogenetra, 360
pseudohermaphrodites, see disorders of sexual
differentiation (DSD)
pseudopregnancy, 360
puerperal tetany, see eclampsia
pyometra, 53–62
clinical features, 55
definition, 53
diagnostics, 55–57
culture and sensitivity, 56
laboratory tests, 55
pathological findings, 57
radiography, 56
ultrasonography, 56–57
etiology/pathophysiology, 53–54
historic findings, 54
risk factors, 54
signalment/history, 54
stump, 53–54
systems affected, 54
therapeutics, 57–60
drug treatment, 59–60
medical treatment, 59
ovariolhysterectomy, 57–58
procedures, 61
supportive care, 59
pyrimethamine and sulfonamides, 440
recombination, 148
regular insulin, 82
relaxin test, 361
renal insufficiency, 226
rennin–angiotensin–aldosterone system (RAAS), 477
saline fluids, for hypercalcemia, 221
Salmonella infection, queen, 461
semen abnormalities, canine, 509–511
clinical features, 509–510
definition, 509
diagnostic procedures, 510–511
differential diagnosis, 510
imaging studies, 510
laboratory tests, 510
pathologic findings, 511
patient monitoring, 511
prevention/avoidance, 511
signalment/history, 509
therapeutics, 511
semen peritonitis, 513–516
clinical features, 514
course and prognosis, 516
definition, 513
diagnostics, 514
differential diagnosis, 514
etiology/pathophysiology, 513
historic findings, 514
pathological findings, 514, 515
patient monitoring, 516
prevention/avoidance, 516
risk factors, 513–514
systems affected, 513
therapeutics, 516
drugs, 516
surgical considerations, 516
sertoli cell tumors, 495–498
clinical features, 495–496
definition, 495
diagnostics, 496
cytology of preputial mucosa, 496–497
ultrasound of testicles, 496–497
differential diagnosis, 496
prognosis, 496
risk factors, 495
esignalment/history, 495
systems affected, 495
therapeutics, 496
sex reversal, see disorders of sexual differentiation (DSD)
sexual differentiation, 109. See also disorders of sexual differentiation (DSD)
sodium, 289. See also hyponatremia
sodium bicarbonate, 193
sodium deficiency, 263
sodium phosphate, 306
Somogyi effect, 83, 95
spironolactone, 429–430, 480
Streptococcus infection, queen, 461
streptozotocin, 322
subinvolution of placental sites (SIPS), 417–422
clinical features, 419
course and prognosis, 422
definition, 417
diagnostics, 419–421
differential diagnosis, 419
etiology/pathophysiology, 417
historic findings, 418
pathologic findings, 421
risk factors, 418
signalment/history, 418
systems affected, 417–418
therapeutics, 421–422
superficial necrolytic dermatitis (SND), 153–154. See also glucagonoma
syndrome of inappropriate antidiuretic hormone secretion (SIADH), 517–520
clinical features, 518
complications, 520
course and prognosis, 520
criteria for diagnosis of, 519
definition, 517
differential diagnosis, 518
etiology/pathophysiology, 517
imaging studies, 519
laboratory tests, 518–519
patient monitoring, 520
signalment/history, 517–518
therapeutics
   drugs, 519
   health care, 519
tamoxifen citrate, for preventing pregnancy, 366
teratospermia, in cat, 462
testis differentiation, 109. See also disorders of sexual differentiation (DSD)
tetracyclines, 453
The 5-Minute Veterinary Consult Clinical Companion
   Canine and Feline Infectious Diseases and Parasitology, 3
thyroid carcinoma, 245. See also hyperthyroidism
thyroidectomy, 258–259
thyroid function tests, 251
  dynamic thyroid function testing, 252–253
  free T4 (FT4) concentration, 252
  serum canine thyroid-stimulating hormone (cTSH) concentration, 252
  serum total T3 concentration, 252
  serum total T4 concentration, 251–252
thyroid gland scintigraphy, 250–251
thyroid nodule, palpation of, 248–249
thyroid-stimulating hormone (TSH), 309
  thyrotoxicosis, see hyperthyroidism
tocodynamometry, 123, 522
Toxoplasma gondii infection
  canine, 437–441
  queen, 462
toxoplasmosis/neosporosis, canine, 437–441
  client education, 441
  clinical features, 438–439
  clinical pathology, 439
cytology, 439
  definition, 437
  differential diagnosis, 439
etiology/pathophysiology, 437–438
  genetics and breed predisposition, 438
  pathological findings, 440
  patient monitoring, 441
  prevention/avoidance, 441
  radiology, 439
  real-time polymerase chain reaction, 440
  risk factors, 438
  serologic testing, 439–440
  systems affected, 438
  therapeutics
    drugs, 440
    precautions/interactions, 440
transcervical endoscopic catheterization technique (TECT), 56
transcervical (intrauterine) insemination (TCI), bitch, 28
transcervical uterine cannulation, 12
trilostane therapy
  for canine hyperadrenocorticism, 170, 173–174
  for feline hyperadrenocorticism, 182
trimethoprim-sulfonamide, 440
trypsin-like immunoreactivity (TLI), 82
Turner syndrome, see disorders of sexual differentiation (DSD)
tylosin, 443

ultrasound
  gestational aging in bitch and queen, 537–542
  ovulation evaluation, 520–534
  for pregnancy diagnosis, 362, 363
  urinary tract infections (UTIs), 84
  urine cortisol:creatinine ratio (UC:Cr), 164
uterine inertia, 120, 521–528
  clinical features, 524
  definition, 521
  differential diagnosis, 524–525
  etiology/pathophysiology, 521
  primary, 521
  secondary, 521
  signalment/history, 521–524
  therapeutics, 526–527
tocodynamometry, use of, 522–524
uterotonics, use of, 525
vinblastine, 503
vincristine sulfate, 494
virus-associated pregnancy loss
  queen, 459, 461–462
vitamin D intoxication, 226
vitamin D preparations, 299
V2 receptor antagonists, 519
vulvovaginal malformations, 549–557
  acquired, 549
  age-related factors, 557
  associated conditions, 556
  biochemistry and urinalysis, 554
  causes and risk factors, 551
  clinical features, 550–551
    historic findings, 550
    physical examination findings, 551
  complications, 556
  congenital, 549
  course and prognosis, 556
  definition, 549
  diagnostic procedures, 551
  differential diagnosis, 551
  digital vaginal examination, 552
  etiology/pathophysiology, 549
  imaging studies, 554
  incidence/prevalence, 550
  patient monitoring, 556
  signalment/history, 550
  systems affected, 550
  therapeutics, 554–556
    client education, 555
    medication, 556
    non-surgical, 554–555
    surgery, 555
  vaginal culture and sensitivity, 551
  vaginal cytology, 551–552
  vaginal speculum, 552
  vaginoscopy, 553–554
weight loss, and hyperthyroidism in cats, 246
Whipple’s triad, 278
white-coat phenomenon, 247